Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad)
NYSE:IBIO

iBio 11/14/2023 Earnings Report

iBio logo
$0.82 +0.03 (+3.15%)
Closing price 04:00 PM Eastern
Extended Trading
$0.80 -0.02 (-2.08%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

iBio EPS Results

Actual EPS
-$4.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Date
11/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

iBio Earnings Headlines

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
May 5, 2025 | finance.yahoo.com
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
May 5, 2025 | globenewswire.com
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
May 23, 2025 | Brownstone Research (Ad)
iBio Reports Fiscal Third Quarter 2025 Financial Results
May 2, 2025 | globenewswire.com
iBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement Transaction
May 1, 2025 | finanznachrichten.de
iBio, Inc. Announces Agreement to Exercise Existing Warrants for $6.2 Million in Gross Proceeds
April 29, 2025 | quiverquant.com
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NYSE:IBIO), a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

View iBio Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles